IBDEI26V ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36753,2)
 ;;=^5001410
 ;;^UTILITY(U,$J,358.3,36754,0)
 ;;=C81.20^^169^1859^54
 ;;^UTILITY(U,$J,358.3,36754,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36754,1,3,0)
 ;;=3^Mixed cellularity classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,36754,1,4,0)
 ;;=4^C81.20
 ;;^UTILITY(U,$J,358.3,36754,2)
 ;;=^5001411
 ;;^UTILITY(U,$J,358.3,36755,0)
 ;;=C81.29^^169^1859^53
 ;;^UTILITY(U,$J,358.3,36755,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36755,1,3,0)
 ;;=3^Mix cellular class Hdgkn lymph, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,36755,1,4,0)
 ;;=4^C81.29
 ;;^UTILITY(U,$J,358.3,36755,2)
 ;;=^5001420
 ;;^UTILITY(U,$J,358.3,36756,0)
 ;;=C81.30^^169^1859^48
 ;;^UTILITY(U,$J,358.3,36756,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36756,1,3,0)
 ;;=3^Lymphocyte depleted classical Hodgkin lymphoma, unsp site
 ;;^UTILITY(U,$J,358.3,36756,1,4,0)
 ;;=4^C81.30
 ;;^UTILITY(U,$J,358.3,36756,2)
 ;;=^5001421
 ;;^UTILITY(U,$J,358.3,36757,0)
 ;;=C81.39^^169^1859^47
 ;;^UTILITY(U,$J,358.3,36757,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36757,1,3,0)
 ;;=3^Lymphocy deplet class Hdgkn lymph, extrnod & solid org site
 ;;^UTILITY(U,$J,358.3,36757,1,4,0)
 ;;=4^C81.39
 ;;^UTILITY(U,$J,358.3,36757,2)
 ;;=^5001430
 ;;^UTILITY(U,$J,358.3,36758,0)
 ;;=C81.40^^169^1859^49
 ;;^UTILITY(U,$J,358.3,36758,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36758,1,3,0)
 ;;=3^Lymphocyte-rich classical Hodgkin lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,36758,1,4,0)
 ;;=4^C81.40
 ;;^UTILITY(U,$J,358.3,36758,2)
 ;;=^5001431
 ;;^UTILITY(U,$J,358.3,36759,0)
 ;;=C81.49^^169^1859^44
 ;;^UTILITY(U,$J,358.3,36759,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36759,1,3,0)
 ;;=3^Lymp-rich class Hodgkin lymph, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36759,1,4,0)
 ;;=4^C81.49
 ;;^UTILITY(U,$J,358.3,36759,2)
 ;;=^5001440
 ;;^UTILITY(U,$J,358.3,36760,0)
 ;;=C81.99^^169^1859^42
 ;;^UTILITY(U,$J,358.3,36760,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36760,1,3,0)
 ;;=3^Hodgkin lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,36760,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,36760,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,36761,0)
 ;;=C81.90^^169^1859^43
 ;;^UTILITY(U,$J,358.3,36761,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36761,1,3,0)
 ;;=3^Hodgkin lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,36761,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,36761,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,36762,0)
 ;;=C82.69^^169^1859^17
 ;;^UTILITY(U,$J,358.3,36762,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36762,1,3,0)
 ;;=3^Cutan folicl center lymphoma, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36762,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,36762,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,36763,0)
 ;;=C82.60^^169^1859^18
 ;;^UTILITY(U,$J,358.3,36763,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36763,1,3,0)
 ;;=3^Cutaneous follicle center lymphoma, unspecified site
 ;;^UTILITY(U,$J,358.3,36763,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,36763,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,36764,0)
 ;;=C82.49^^169^1859^33
 ;;^UTILITY(U,$J,358.3,36764,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36764,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,36764,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,36764,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,36765,0)
 ;;=C82.40^^169^1859^34
 ;;^UTILITY(U,$J,358.3,36765,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36765,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, unspecified site
